Ctla 4
Mostrando 1-12 de 154 artigos, teses e dissertações.
-
1. Association between the CTLA4 +49A/G (rs231775) and CT60 (rs3087243) gene variants with vitiligo: study on a Mexican population
Abstract Background: Vitiligo is characterized by an autoimmune response targeting melanocytes, thus resulting in skin depigmentation. There are several genetic components involved in the development of vitiligo, of which various gene polymorphisms are currently considered as risk factors. For example, the CTLA4 (T-lymphocyte antigen 4) +49A/G (rs231775) an
Anais Brasileiros de Dermatologia. Publicado em: 2022
-
2. Mild and asymptomatic cases of COVID-19 are potential threat for faecal–oral transmission
SUMMARY Checkpoint inhibitors have substantially improved the prognosis for patients with advanced malignancy. Treatment with immunomodulants has the ability to reactivate the immune system against tumor cells, but can also trigger the development of immune-related adverse events that reflects a loss of tolerance of the immune system for self-antigens. Regar
Braz J Infect Dis. Publicado em: 2020-08
-
3. Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy
SUMMARY Checkpoint inhibitors have substantially improved the prognosis for patients with advanced malignancy. Treatment with immunomodulants has the ability to reactivate the immune system against tumor cells, but can also trigger the development of immune-related adverse events that reflects a loss of tolerance of the immune system for self-antigens. Regar
Arch. Endocrinol. Metab.. Publicado em: 2020-08
-
4. CTLA4 +49AG (rs231775) and CT60 (rs3087243) gene variants are not associated with alopecia areata in a Mexican population from Monterrey Mexico,
Abstract Background: Alopecia areata is an autoimmune disease that produces non-scarring hair loss around the body. Gene variants of the cytotoxic T-lymphocyte antigen 4 (CTLA4) gene, a negative regulator of T-cell response, have been associated with a predisposition to autoimmune diseases in different populations; however, the involvement of these genetic
An. Bras. Dermatol.. Publicado em: 2020-06
-
5. CTLA-4 gene polymorphisms are associated with obesity in Turner Syndrome
Abstract Turner syndrome (TS) is characterized by a set of clinical conditions, including autoimmune/inflammatory diseases and infectious conditions, that can compromise a patient’s quality of life. Here we assessed polymorphisms in CTLA-4 +49A/G (rs231775), PTPN22 +1858G/A (rs2476601), and MBL2 -550 (H/L) (rs11003125), -221(X/Y) (rs7096206) and exon 1 (A/
Genet. Mol. Biol.. Publicado em: 29/11/2018
-
6. O papel de células T regulatórias, da interleucina 10 e da cintilografica in vivo em doenças autoimunes e idiopáticas – Perspectivas terapêuticas e prognóstico
Resumo Estudos anteriores já haviam demonstrado a expressão do marcador CD25 na superfície de células T de ocorrência natural (Tregs) de camundongos, que apresentam perfil celular autorreativo. Recentemente, foi detectada, em subtipos de linfócitos de indivíduos acometidos por doenças autoimunes e de causa idiopática, a expressão de outros marcador
Rev. Assoc. Med. Bras.. Publicado em: 2017-12
-
7. Belatacept no transplante renal - perspectivas passadas e futuras
Resumo Os inibidores da calcineurina (INC) são amplamente utilizados para a imunossupressão de manutenção em pacientes receptores de transplante renal. No entanto, o seu perfil de efeitos colaterais tem levado os pesquisadores a tentar encontrar alternativas mais seguras, que possam manter efetiva imunossupressão de longo prazo com menos toxicidade. O B
J. Bras. Nefrol.. Publicado em: 2017-06
-
8. Melanoma: tumor microenvironment and new treatments
Abstract: In the recent past years, many discoveries in the tumor microenvironment have led to changes in the management of melanoma and it is rising up hopes, specially, to those in advanced stages. FDA approved seven new drugs from 2011 to 2014. They are: Vemurafenib, Dabrafenib and Trametinib, kinases inhibitors used for patients that have BRAFV600E mutat
An. Bras. Dermatol.. Publicado em: 2017-03
-
9. Tratamento de melanoma avançado - Um panorama em transformação
Resumo Após décadas de ostracismo, os recentes avanços no tratamento do melanoma trouxeram uma nova realidade para pacientes, médicos e pesquisadores. Enquanto anticorpos monoclonais voltados a moléculas envolvidas na modulação da interação entre células do melanoma e do sistema imune consolidaram o uso da “imunoterapia”, um melhor conhecimento
Rev. Assoc. Med. Bras.. Publicado em: 2017
-
10. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a negative regulator of T cell activation, which competes with CD28 for B7.1/B7.2 binding, and which has a greater affinity. Fusion of specific antigens to extracellular domain of CTLA4 represents a promising approach to increase the immunogenicity of DNA vaccines. In this study, we evaluated this inter
Braz J Med Biol Res. Publicado em: 24/10/2016
-
11. CTLA4 enhances the osteogenic differentiation of allogeneic human mesenchymal stem cells in a model of immune activation
Allogeneic mesenchymal stem cells (allo-MSCs) have recently garnered increasing interest for their broad clinical therapy applications. Despite this, many studies have shown that allo-MSCs are associated with a high rate of graft rejection unless immunosuppressive therapy is administered to control allo-immune responses. Cytotoxic T-lymphocyte-associated pro
Braz J Med Biol Res. Publicado em: 19/05/2015
-
12. Imbalanced expression of functional surface molecules in regulatory and effector T cells in systemic lupus erythematosus
Regulatory T (TREG) cells play an important role in maintaining immune tolerance and avoiding autoimmunity. We analyzed the expression of membrane molecules in TREG and effector T cells in systemic lupus erythematosus (SLE). TREG and effector T cells were analyzed for the expression of CTLA-4, PD1, CD28, CD95, GITR, HLA-DR, OX40, CD40L, and CD45RO in 26 pati
Braz J Med Biol Res. Publicado em: 2014-08